In GetGoal-Mono Japan, Japanese patients experienced a 0.74% and 0.99% reduction in HbA 1c (one-step or two-step dose increase, respectively) at week 24, which was sustained at week 76 (reduction of 0.72% across both groups) from a baseline HbA 1c of 66 mmol/mol (8.2%)
Simultaneously, long-chain acyl-CoA synthetase 4 (ACSL4) expression decreases, reducing the availability of oxidizable PUFAs, although the exact mechanism underlying this remains unclear
But so far, the safety profile looks manageable
HDAC1 has been implicated in reducing the human immunodeficiency viruses activity in infected cells
Young: Right, so Novo Nordisk essentially sued Hims & Hers because they were saying that, Hey, youre mismarketing your compounded GLP-1s as essentially a first go-to drug instead of our drug. They also were alleging them to be, like, copycats. And these drugs under Novo Nordisk and similarly Eli Lilly, theyre still under patent
Proc Natl Acad Sci U S A 91(8):32423246
